SpringerLink
Log in

NSAIDs, Pharmacogenetics

  • Reference work entry
Encyclopedia of Pain

  • 109 Accesses

Synonyms

Inherited variability of drug response

Definition

Pharmacogenetics seeks to explore how genetic variants influence the pharmacokinetic and pharmacodynamic properties of a given drug by determining how mutations in the genes which encode drug-metabolizing enzymes, drug targets, and drug transporters influence drug response.

Characteristics

Nonsteroidal anti-inflammatory drugs (NSAID) block the formation of prostaglandins by inhibiting the rate-limiting cyclooxygenase (COX) enzymes, COX-1 and COX-2, also known as prostaglandin H2 synthases (PGHS1 and PGHS2). Since prostaglandins participate in mediating the inflammatory response, the pharmacological activity of NSAIDs consists mainly of antinociceptive, anti-inflammatory, and antipyretic properties.

Variation of this pharmacological activity can arise as a basic principle from mutations in proteins, which (i) influence the bioavailability of a drug, (ii) vary the binding affinity to the drug target, or (iii) modify drug...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 1,799.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 549.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abdullah, L., et al. (2006). The cyclooxygenase 2-765 C promoter allele is a protective factor for Alzheimer’s disease. Neuroscience Letters, 395, 240–243.

    PubMed  CAS  Google Scholar 

  • Aithal, G. P., Day, C. P., Leathart, J. B., & Daly, A. K. (2000). Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics, 10, 511–518.

    PubMed  CAS  Google Scholar 

  • Arisawa, T., et al. (2007). Association between genetic polymorphisms in the cyclooxygenase-1 gene promoter and peptic ulcers in Japan. International Journal of Molecular Medicine, 20, 373–378.

    PubMed  CAS  Google Scholar 

  • Arisawa, T., et al. (2008). Genetic polymorphisms of cyclooxygenase-1 (COX-1) are associated with functional dyspepsia in Japanese women. Journal of Women’s Health (Larchmt), 17, 1039–1043.

    Google Scholar 

  • Baillie, T. A., et al. (2001). Mechanistic studies on the reversible metabolism of rofecoxib to 5-hydroxyrofecoxib in the rat: Evidence for transient ring opening of a substituted 2-furanone derivative using stable isotope-labeling techniques. Drug Metabolism and Disposition, 29, 1614–1628.

    PubMed  CAS  Google Scholar 

  • Blanco, G., et al. (2008). Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. Pharmacogenetics and Genomics, 18, 37–43.

    PubMed  CAS  Google Scholar 

  • Cipollone, F., et al. (2004). A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA, 291, 2221–2228.

    PubMed  CAS  Google Scholar 

  • Colaizzo, D., et al. (2006). The COX-2 G/C-765 polymorphism may modulate the occurrence of cerebrovascular ischemia. Blood Coagulation & Fibrinolysis, 17, 93–96.

    CAS  Google Scholar 

  • Daly, A. K., Aithal, G. P., Leathart, J. B., Swainsbury, R. A., Dang, T. S., & Day, C. P. (2007). Genetic susceptibility to diclofenac-induced hepatotoxicity: Contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology, 132, 272–281.

    PubMed  CAS  Google Scholar 

  • Daraei, A., Salehi, R., & Mohamadhashem, F. (2012). PTGS2 (COX2)-765 G>C gene polymorphism and risk of sporadic colorectal cancer in Iranian population. Molecular Biology Reports, 39, 5219–5224.

    PubMed  CAS  Google Scholar 

  • Estany-Gestal, A., Salgado-Barreira, A., Sanchez-Diz, P., & Figueiras, A. (2011). Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs: A systematic critical review. Pharmacogenetics and Genomics, 21, 357–364.

    PubMed  CAS  Google Scholar 

  • Feher, A., Juhasz, A., Rimanoczy, A., Kalman, J., & Janka, Z. (2010). Association study of interferon-gamma, cytosolic phospholipase A2, and cyclooxygenase-2 gene polymorphisms in Alzheimer disease. The American Journal of Geriatric Psychiatry, 18, 983–987.

    PubMed  Google Scholar 

  • Frank, B., Hoffmeister, M., Klopp, N., Illig, T., Chang-Claude, J., & Brenner, H. (2010). Polymorphisms in inflammatory pathway genes and their association with colorectal cancer risk. International Journal of Cancer, 127, 2822–2830.

    CAS  Google Scholar 

  • Fries, S., et al. (2006). Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology, 130, 55–64.

    PubMed  CAS  Google Scholar 

  • Garcia-Martin, E., Martinez, C., Tabares, B., Frias, J., & Agundez, J. A. (2004). Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clinical Pharmacology and Therapeutics, 76, 119–127.

    PubMed  CAS  Google Scholar 

  • Gunnarsson, I., Kanerud, L., Pettersson, E., Lundberg, I., Lindblad, S., & Ringertz, B. (1997). Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. British Journal of Rheumatology, 36, 1089–1094.

    PubMed  CAS  Google Scholar 

  • Halushka, M. K., & Halushka, P. V. (2006). Toward individualized analgesic therapy: Functional cyclooxygenase 1 and 2 haplotypes. Clinical Pharmacology and Therapeutics, 79, 404–406.

    PubMed  Google Scholar 

  • Halushka, M. K., Walker, L. P., & Halushka, P. V. (2003). Genetic variation in cyclooxygenase 1: Effects on response to aspirin. Clinical Pharmacology and Therapeutics, 73, 122–130.

    PubMed  CAS  Google Scholar 

  • Hegener, H. H., Diehl, K. A., Kurth, T., Gaziano, J. M., Ridker, P. M., & Zee, R. Y. (2006). Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: A nested case-control approach. Journal of Thrombosis and Haemostasis, 4, 1718–1722.

    PubMed  CAS  Google Scholar 

  • Helmersson, J., Arnlov, J., Axelsson, T., & Basu, S. (2009). A polymorphism in the cyclooxygenase 1 gene is associated with decreased inflammatory prostaglandin F2alpha formation and lower risk of cardiovascular disease. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 80, 51–56.

    PubMed  CAS  Google Scholar 

  • Hernandez, E. M., Chan, C. H., Xu, B., Notario, V., & Richert, J. R. (2004). Role of an internal ribosome entry site in the translational control of the human transcription factor Sp3. International Journal of Oncology, 24, 719–724.

    PubMed  CAS  Google Scholar 

  • Karim, A., et al. (2000). Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects. Journal of Clinical Pharmacology, 40, 655–663.

    PubMed  CAS  Google Scholar 

  • Kim, H., Ramsay, E., Lee, H., Wahl, S., & Dionne, R. A. (2009). Genome-wide association study of acute post-surgical pain in humans. Pharmacogenomics, 10, 171–179.

    PubMed  CAS  Google Scholar 

  • Kirchheiner, J., Meineke, I., Freytag, G., Meisel, C., Roots, I., & Brockmoller, J. (2002). Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clinical Pharmacology and Therapeutics, 72, 62–75.

    PubMed  CAS  Google Scholar 

  • Kirchheiner, J., Stormer, E., Meisel, C., Steinbach, N., Roots, I., & Brockmoller, J. (2003). Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics, 13, 473–480.

    PubMed  CAS  Google Scholar 

  • Kohsaka, S., et al. (2008). Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: The Atherosclerosis risk in communities study. Atherosclerosis, 196, 926–930.

    PubMed  CAS  Google Scholar 

  • Konheim, Y. L., & Wolford, J. K. (2003). Association of a promoter variant in the inducible cyclooxygenase-2 gene (PTGS2) with type 2 diabetes mellitus in Pima Indians. Human Genetics, 113, 377–381.

    PubMed  CAS  Google Scholar 

  • Kury, S., et al. (2008). Low-penetrance alleles predisposing to sporadic colorectal cancers: A French case-controlled genetic association study. BMC Cancer, 8, 326–341.

    PubMed  Google Scholar 

  • Lee, C. R., Pieper, J. A., Frye, R. F., Hinderliter, A. L., Blaisdell, J. A., & Goldstein, J. A. (2003). Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. European Journal of Clinical Pharmacology, 58, 791–794.

    PubMed  CAS  Google Scholar 

  • Lee, Y. S., Kim, H., Wu, T. X., Wang, X. M., & Dionne, R. A. (2006). Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. Clinical Pharmacology and Therapeutics, 79, 407–418.

    PubMed  CAS  Google Scholar 

  • Lee, C. R., et al. (2007). Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1). Pharmacogenetics and Genomics, 17, 145–160.

    PubMed  CAS  Google Scholar 

  • Lee, C. R., North, K. E., Bray, M. S., Couper, D. J., Heiss, G., & Zeldin, D. C. (2008). Cyclooxygenase polymorphisms and risk of cardiovascular events: The Atherosclerosis Risk in Communities (ARIC) study. Clinical Pharmacology and Therapeutics, 83, 52–60.

    PubMed  CAS  Google Scholar 

  • Li, W., et al. (2009). Cyclooxygenase-2 (COX-2) G-765C is a protective factor for coronary artery disease but not for ischemic stroke: A meta-analysis. Atherosclerosis, 207, 492–495.

    PubMed  CAS  Google Scholar 

  • Liang, Y., Liu, J. L., Wu, Y., Zhang, Z. Y., & Wu, R. (2011). Cyclooxygenase-2 polymorphisms and susceptibility to esophageal cancer: A meta-analysis. The Tohoku Journal of Experimental Medicine, 223, 137–144.

    PubMed  CAS  Google Scholar 

  • Listi, F., et al. (2010). Role of cyclooxygenase-2 and 5-lipoxygenase polymorphisms in Alzheimer’s disease in a population from northern Italy: Implication for pharmacogenomics. Journal of Alzheimer’s Disease, 19, 551–557.

    PubMed  CAS  Google Scholar 

  • Maguire, J., et al. (2011). Impact of COX-2 rs5275 and rs20417 and GPIIIa rs5918 polymorphisms on 90-day ischemic stroke functional outcome: A novel finding. Journal of Stroke and Cerebrovascular Diseases, 20, 134–144.

    PubMed  Google Scholar 

  • Malhi, H., Atac, B., Daly, A. K., & Gupta, S. (2004). Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication. Postgraduate Medical Journal, 80, 107–109.

    PubMed  CAS  Google Scholar 

  • Montali, A., et al. (2010). Functional rs20417 SNP (-765G>C) of cyclooxygenase-2 gene does not predict the risk of recurrence of ischemic events in coronary patients: Results of a 7-year prospective study. Cardiology, 115, 236–242.

    PubMed  CAS  Google Scholar 

  • Ohtani, T., Hiroi, A., Sakurane, M., & Furukawa, F. (2003). Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine. British Journal of Dermatology, 148, 1035–1039.

    PubMed  CAS  Google Scholar 

  • Ol, K. K., Agachan, B., Gormus, U., Toptas, B., & Isbir, T. (2011). Cox-2 gene polymorphism and IL-6 levels in coronary artery disease. Genetics and Molecular Research, 10, 810–816.

    PubMed  CAS  Google Scholar 

  • Papafili, A., et al. (2002). Common promoter variant in cyclooxygenase-2 represses gene expression: Evidence of role in acute-phase inflammatory response. Arteriosclerosis, Thrombosis, and Vascular Biology, 22, 1631–1636.

    PubMed  CAS  Google Scholar 

  • Peters, M. J., et al. (2012). Genome-wide association study meta-analysis of chronic widespread pain: Evidence for involvement of the 5p15.2 region. Annals of the Rheumatic Diseases, 72(3), 427–3.

    PubMed  Google Scholar 

  • Reyes-Gibby, C. C., et al. (2009). Role of inflammation gene polymorphisms on pain severity in lung cancer patients. Cancer epidemiology, biomarkers & prevention: A publication of the American Association for Cancer Research. American Society of Preventive Oncology, 18, 2636–2642.

    CAS  Google Scholar 

  • Sabbagh, N., Delaporte, E., Marez, D., Lo-Guidice, J. M., Piette, F., & Broly, F. (1997). NAT2 genoty** and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus. Pharmacogenetics, 7, 131–135.

    PubMed  CAS  Google Scholar 

  • Schneider, E. M., et al. (2011). The (-765 G–>C) promoter variant of the COX-2/PTGS2 gene is associated with a lower risk for end-stage hip and knee osteoarthritis. Annals of the Rheumatic Diseases, 70, 1458–1460.

    PubMed  CAS  Google Scholar 

  • Sharma, V., Kaul, S., Al-Hazzani, A., Alshatwi, A. A., Jyothy, A., & Munshi, A. (2013). Association of COX-2 rs20417 with aspirin resistance. Journal of Thrombosis and Thrombolysis, 35, 95–99.

    PubMed  CAS  Google Scholar 

  • Skarke, C., et al. (2006). The cyclooxygenase 2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production. Clinical Pharmacology and Therapeutics, 80, 621–632.

    PubMed  CAS  Google Scholar 

  • Skarke, C., Schuss, P., Kirchhof, A., Doehring, A., Geisslinger, G., & Lotsch, J. (2007). Pyrosequencing of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance. Pharmacogenomics, 8, 1643–1660.

    PubMed  CAS  Google Scholar 

  • Szczeklik, W., Sanak, M., & Szczeklik, A. (2004). Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. The Journal of Allergy and Clinical Immunology, 114, 248–253.

    PubMed  CAS  Google Scholar 

  • Tanaka, E., et al. (2002). Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. Journal of Rheumatology, 29, 2492–2499.

    PubMed  CAS  Google Scholar 

  • Tanigawara, Y., et al. (2002). N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events. Biological and Pharmaceutical Bulletin, 25, 1058–1062.

    PubMed  CAS  Google Scholar 

  • Ueda, N., Maehara, Y., Tajima, O., Tabata, S., Wakabayashi, K., & Kono, S. (2008). Genetic polymorphisms of cyclooxygenase-2 and colorectal adenoma risk: The self defense forces health study. Cancer Science, 99, 576–581.

    PubMed  CAS  Google Scholar 

  • Ulrich, C. M., et al. (2002). Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations. Human Mutation, 20, 409–410.

    PubMed  Google Scholar 

  • Ulrich, C. M., et al. (2005). PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiology, Biomarkers & Prevention, 14, 616–619.

    CAS  Google Scholar 

  • Werner, U., Werner, D., Rau, T., Fromm, M. F., Hinz, B., & Brune, K. (2003). Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clinical Pharmacology and Therapeutics, 74, 130–137.

    PubMed  CAS  Google Scholar 

  • Yasar, U., et al. (2002). Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochemical and Biophysical Research Communications, 299, 25–28.

    PubMed  CAS  Google Scholar 

  • Yazdanian, M., Briggs, K., Jankovsky, C., & Hawi, A. (2004). The “high solubility” definition of the current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs. Pharmaceutical Research, 21, 293–299.

    PubMed  CAS  Google Scholar 

  • Zhang, J. Y., Zhan, J., Cook, C. S., Ings, R. M., & Breau, A. P. (2003). Involvement of human UGT2B7 and 2B15 in rofecoxib metabolism. Drug Metabolism and Disposition, 31, 652–658.

    PubMed  Google Scholar 

  • Zhang, X., et al. (2005). Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology, 129, 565–576.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania Perelman School of Medicine, 8036 Maloney Bldg., 3600 Spruce St, Philadelphia, PA, 19104, USA

    Carsten Skarke

  2. Department of Neurosurgery, University-Hospital Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Germany

    Patrick Schuss

Authors
  1. Carsten Skarke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick Schuss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carsten Skarke .

Editor information

Editors and Affiliations

  1. Department of Anesthesiology, Center for Pain Research, University of Pittsburgh, Pittsburgh, PA, USA

    Gerald F. Gebhart

  2. Physiologisches Institut der, Universität Würzburg, Würzburg, Germany

    Robert F. Schmidt

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this entry

Cite this entry

Skarke, C., Schuss, P. (2013). NSAIDs, Pharmacogenetics. In: Gebhart, G.F., Schmidt, R.F. (eds) Encyclopedia of Pain. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-28753-4_2852

Download citation

Publish with us

Policies and ethics

Search

Navigation